Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study
Authors' conclusion
In T2DM patients receiving CRTd, combination therapy with GLP-1RAs/SGLT2i was associated with improvements in cardiac function and clinical outcomes compared to monotherapy. GLP-1RAs/SGLT2i could optimize CRT responsiveness and reduce HF-hospitalizations in T2DM patients.
Study context
- Population
- T2D patients treated with CRT with defibrillator (cardiac-resynchronization-therapy-with-defibrillator (CRTd)) on chronic anti-diabetic medications
- Participants
- 2,257 patients
- Exposure
- GLP-1 RA/SGLT2i combination therapy vs SGLT2i or GLP-1 RA monotherapy
- Combinationn = 575
- SGLT2in = 874reference
- GLP-1RAsn = 808reference
- Outcome
- CRT response and HF hospitalizations
- Follow-up
- 1-year follow-up
Main finding
As reported in the abstract
1 year
CombinationHazard ratio (95 % CI)P value
Multivariate Cox; independent predictor of CRT response
1.659(1.320–2.085)
p 0.001- Multivariate Cox; reduced heart failure (HF) hospitalizations
- 0.822 (95 % CI 0.751–0.966); p0.012
Observational data: associations, not effects.
Original publication
Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study. Diabetes Res Clin Pract. Published 3 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →